← Back to Search

Other

SY-201 Ophthalmic Solution 2.0% for Dry Eye Syndrome

Phase 1 & 2
Waitlist Available
Research Sponsored by Seinda Pharmaceutical Guangzhou Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days

Summary

This trial is testing an eye drop treatment called SY-201 Ophthalmic Solution. It aims to see if the eye drops are safe and effective for people who have dry eye disease. The study will compare the eye drops to another group over a few months.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Eye dryness score
Total corneal fluorescein staining
Secondary study objectives
Adverse event

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: SY-201 Ophthalmic Solution 2.0%Experimental Treatment1 Intervention
SY-201 Ophthalmic Solution 2.0%
Group II: SY-201 Ophthalmic Solution 1.0%Experimental Treatment1 Intervention
SY-201 Ophthalmic Solution 1.0%
Group III: SY-201 Ophthalmic Solution 0.5%Experimental Treatment1 Intervention
SY-201 Ophthalmic Solution 0.5%
Group IV: SY-201 Ophthalmic Solution VehiclePlacebo Group1 Intervention
SY-201 Ophthalmic Solution Vehicle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SY-201 Ophthalmic Solution 2.0%
2022
Completed Phase 2
~210
SY-201 Ophthalmic Solution 0.5%
2022
Completed Phase 2
~210
SY-201 Ophthalmic Solution 1.0%
2022
Completed Phase 2
~210

Find a Location

Who is running the clinical trial?

Seinda Pharmaceutical Guangzhou CorporationLead Sponsor
~62 spots leftby Nov 2025